全基因组CRISPR筛选鉴定丝裂原活化蛋白激酶调控因子为小鼠肝脏肿瘤抑制因子
研究采用全基因组CRISPR/Cas9敲除筛选,在过表达MYC的P53缺失小鼠胚胎肝祖细胞中靶向20611个小鼠基因,鉴定出Nf1、Plxnb1、Flrt2和B9d1四个既往未与肝癌关联的候选肝脏肿瘤抑制基因。Nf1敲除加速小鼠肝脏肿瘤形成,Nf1缺失或RAS激活上调HMGA2和SOX9;人肝细胞癌中NF1信使RNA低水平或HMGA2信使RNA高水平与患者生存时间缩短相关。
要点
- 全基因组CRISPR筛选鉴定Nf1、Plxnb1、Flrt2和B9d1为小鼠肝脏肿瘤抑制因子。
- Nf1敲除加速小鼠肝脏肿瘤形成,RAS-MAPK信号通路参与肝脏肿瘤形成。
- 人肝细胞癌中NF1信使RNA低水平或HMGA2信使RNA高水平与患者生存时间缩短相关。
核心结论
- 采用基于CRISPR的策略,鉴定Nf1、Plxnb1、Flrt2和B9d1为肝脏肿瘤形成的抑制因子。
- 验证了RAS信号通过丝裂原活化蛋白激酶促进小鼠肝脏肿瘤形成的观察。
- 将NF1水平降低及其下游蛋白HMGA2水平升高与肝细胞癌患者生存时间相关联。
- 作者认为,可能开发抑制或减少HMGA2的策略来治疗肝癌患者。
研究设计与样本
- 研究为全基因组CRISPR/Cas9敲除筛选:对过表达MYC的P53缺失小鼠胚胎肝祖细胞,用含67000条单引导RNA(sgRNA)、靶向20611个小鼠基因的mGeCKOa慢病毒文库感染p53-/-;Myc;Cas9肝细胞,并将转导细胞皮下移植入裸鼠。
- 1个月内,所有接受sgRNA文库的小鼠均发生皮下肿瘤;对肿瘤DNA进行高通量测序,鉴定出较初始细胞池增加至少8倍的sgRNA。
- 为验证筛选出的前10个候选肿瘤抑制因子,利用癌症基因组图谱(Cancer Genome Atlas)和COSMIC数据库收集肝细胞癌(HCC)患者数据。
- 用CRISPR在p53-/-;Myc;Cas9细胞中失活候选肿瘤抑制基因并皮下移植入裸鼠,监测肿瘤形成并用组织学和免疫组化分析肿瘤。
- 对肝脏特异性p53破坏的小鼠,经流体动力学尾静脉注射编码Myc和针对候选肿瘤抑制因子的sgRNA/Cas9质粒,监测肿瘤生长和转移。
主要发现
- 鉴定出4个既往未与肝癌关联的候选肝脏肿瘤抑制基因:Nf1、Plxnb1、Flrt2和B9d1。
- CRISPR介导的Nf1(RAS负调控因子)敲除加速小鼠肝脏肿瘤形成。
- Nf1缺失或RAS激活上调肝脏祖细胞标志物HMGA2和SOX9;RAS通路抑制剂抑制由Nf1缺失或RAS致癌激活导致的Hmga2和Sox9基因激活。
- 敲低HMGA2延迟表达致癌RAS的细胞形成异种移植肿瘤。
- 人肝细胞癌中,NF1信使RNA低水平或HMGA2信使RNA高水平与患者生存时间缩短相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: It has been a challenge to identify liver tumor suppressors or oncogenes due to the genetic heterogeneity of these tumors. We performed a genome-wide screen to identify suppressors of liver tumor formation in mice, using CRISPR-mediated genome editing. METHODS: We performed a genome-wide CRISPR/Cas9-based knockout screen of P53-null mouse embryonic liver progenitor cells that overexpressed MYC. We infected p53-/-;Myc;Cas9 hepatocytes with the mGeCKOa lentiviral library of 67,000 single-guide RNAs (sgRNAs), targeting 20,611 mouse genes, and transplanted the transduced cells subcutaneously into nude mice. Within 1 month, all the mice that received the sgRNA library developed subcutaneous tumors. We performed high-throughput sequencing of tumor DNA and identified sgRNAs increased at least 8-fold compared to the initial cell pool. To validate the top 10 candidate tumor suppressors from this screen, we collected data from patients with hepatocellular carcinoma (HCC) using the Cancer Genome Atlas and COSMIC databases. We used CRISPR to inactivate candidate tumor suppressor genes in p53-/-;Myc;Cas9 cells and transplanted them subcutaneously into nude mice; tumor formation was monitored and tumors were analyzed by histology and immunohistochemistry. Mice with liver-specific disruption of p53 were given hydrodynamic tail-vein injections of plasmids encoding Myc and sgRNA/Cas9 designed to disrupt candidate tumor suppressors; growth of tumors and metastases was monitored. We compared gene expression profiles of liver cells with vs without tumor suppressor gene disrupted by sgRNA/Cas9. Genes found to be up-regulated after tumor suppressor loss were examined in liver cancer cell lines; their expression was knocked down using small hairpin RNAs, and tumor growth was examined in nude mice. Effects of the MEK inhibitors AZD6244, U0126, and trametinib, or the multi-kinase inhibitor sorafenib, were examined in human and mouse HCC cell lines. RESULTS: We identified 4 candidate liver tumor suppressor genes not previously associated with liver cancer (Nf1, Plxnb1, Flrt2, and B9d1). CRISPR-mediated knockout of Nf1, a negative regulator of RAS, accelerated liver tumor formation in mice. Loss of Nf1 or activation of RAS up-regulated the liver progenitor cell markers HMGA2 and SOX9. RAS pathway inhibitors suppressed the activation of the Hmga2 and Sox9 genes that resulted from loss of Nf1 or oncogenic activation of RAS. Knockdown of HMGA2 delayed formation of xenograft tumors from cells that expressed oncogenic RAS. In human HCCs, low levels of NF1 messenger RNA or high levels of HMGA2 messenger RNA were associated with shorter patient survival time. Liver cancer cells with inactivation of Plxnb1, Flrt2, and B9d1 formed more tumors in mice and had increased levels of mitogen-activated protein kinase phosphorylation. CONCLUSIONS: Using a CRISPR-based strategy, we identified Nf1, Plxnb1, Flrt2, and B9d1 as suppressors of liver tumor formation. We validated the observation that RAS signaling, via mitogen-activated protein kinase, contributes to formation of liver tumors in mice. We associated decreased levels of NF1 and increased levels of its downstream protein HMGA2 with survival times of patients with HCC. Strategies to inhibit or reduce HMGA2 might be developed to treat patients with liver cancer.
引用
- Song CQ, Li Y, Mou H, et al. Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. Gastroenterology. 2016. PMID: 27956228. doi:10.1053/j.gastro.2016.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。